New directions in targeting protein kinases: focusing upon true allosteric and bivalent inhibitors.

Department of Chemistry and Biochemistry, University of Arizona, 1306 East University Blvd, Tucson, AZ 85721, USA.
Current pharmaceutical design (Impact Factor: 4.41). 05/2012; 18(20):2936-45.
Source: PubMed

ABSTRACT Over the past decade, therapeutics that target subsets of the 518 human protein kinases have played a vital role in the fight against cancer. Protein kinases are typically targeted at the adenosine triphosphate (ATP) binding cleft by type I and II inhibitors, however, the high sequence and structural homology shared by protein kinases, especially at the ATP binding site, inherently leads to polypharmacology. In order to discover or design truly selective protein kinase inhibitors as both pharmacological reagents and safer therapeutic leads, new efforts are needed to target kinases outside the ATP cleft. Recent advances include the serendipitous discovery of type III inhibitors that bind a site proximal to the ATP pocket as well as the truly allosteric type IV inhibitors that target protein kinases distal to the substrate binding pocket. These new classes of inhibitors are often selective but usually display moderate affinities. In this review we will discuss the different classes of inhibitors with an emphasis on bisubstrate and bivalent inhibitors (type V) that combine different inhibitor classes. These inhibitors have the potential to couple the high affinity and potency of traditional active site targeted small molecule inhibitors with the selectivity of inhibitors that target the protein kinase surface outside ATP cleft.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Significance: Protein tyrosine phosphatases (PTPs) are important enzymes involved in the regulation of cellular signaling. Evidence accumulated over the years has indicated that PTPs present exciting opportunities for drug discovery against diseases like diabetes, cancer, autoimmune diseases, and tuberculosis. However the highly conserved and partially positive charge of the catalytic sites of PTPs are major challenges in the development of potent and highly selective PTP inhibitors. Recent Advances: Here we examine the strategy of developing bidentate inhibitors for selective inhibition of PTPs. Bidentate inhibitors are small molecular weight compounds with the ability to bind to both the active site and a non-conserved secondary phosphate binding site. This secondary phosphate binding site was initially discovered in PTP1B and hence most of the bidentate inhibitors reported in this review are PTP1B inhibitors. Critical Issues: Although bidentate inhibition is a good strategy for developing potent and selective inhibitors, the cell membrane permeability and pharmacokinetic properties of the inhibitors are also important for successful drug development. In this review, we will also summarize the various efforts made towards the development of phosphotyrosine (pTyr) mimetics for increasing cellular permeability. Future Directions: Even though the secondary phosphate binding site was initially found in PTP1B, structural data has shown that a secondary binding site can also be found in other PTPs, albeit with varying degrees of accessibility. Together with improvements in pTyr mimetics, we believe that the future will see an increase in the number of orally bioavailable bidentate inhibitors against the various classes of PTPs.
    Antioxidants & Redox Signaling 11/2013; · 8.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A novel strategy to prepare bisubstrate based inhibitors for histone acetyltransferases is presented. To obtain these, azido peptides derived from histone H3 incorporating either a serine or a phosphoserine residue were connected to a propargyl coenzyme A derivative through copper catalyzed click chemistry. The resulting inhibitors were tested with therapeutically relevant acetyltransferase PCAF. Increased potency of the phosphoserine containing inhibitor was observed. The synthetic strategy presented may be used for developing bisubstrate based inhibitors against any acetyltransferase.
    Bioorganic & medicinal chemistry letters 12/2013; · 2.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Allostery is the most direct and efficient way for regulation of biological macromolecule function, ranging from the control of metabolic mechanisms to signal transduction pathways. Allosteric modulators target to allosteric sites, offering distinct advantages compared to orthosteric ligands that target to active sites, such as greater specificity, reduced side effects, and lower toxicity. Allosteric modulators have therefore drawn increasing attention as potential therapeutic drugs in the design and development of new drugs. In recent years, advancements in our understanding of the fundamental principles underlying allostery, coupled with the exploitation of powerful techniques and methods in the field of allostery, provide unprecedented opportunities to discover allosteric proteins, detect and characterize allosteric sites, design and develop novel efficient allosteric drugs, and recapitulate the universal features of allosteric proteins and allosteric modulators. In the present review, we summarize the recent advances in the repertoire of allostery, with a particular focus on the aforementioned allosteric compounds.
    Medicinal Research Reviews 05/2014; · 9.58 Impact Factor